Eli Lilly and Co., US5324571083

China approval: Eli Lilly stock gains 0.93% premarket to EUR 1,316.30

Published on 11/16/2026 at 08:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
China has approved Eli Lilly's oral weight-loss medicine orforglipron, giving the company an early position in a major obesity-drug market. On Xetra, the stock closed at EUR 1,304.20 on Friday, November 13, 2026.

China Expands Lilly's Obesity Opportunity

  • China approved orforglipron as its first oral GLP-1 weight-loss pill.
  • Lilly is preparing the commercial launch and will supply authorized healthcare and pharmaceutical institutions.
  • The approval gives Lilly an early position against Novo Nordisk in China's obesity-drug market.
Eli Lilly and Co., US5324571083, Illustration mit AI erstellt.

China has approved Eli Lilly's oral weight-loss medicine orforglipron, giving the US drugmaker an early position in the country's market for obesity treatments. The decision makes Lilly the first drugmaker to win Chinese approval for an oral GLP-1 weight-loss pill.

Reuters, published by the Raleigh News & Observer, said on November 12 that Lilly was working to advance the commercial launch in China. The company did not disclose pricing and plans to supply the pill to authorized healthcare and pharmaceutical institutions.

Eli Lilly stock traded at 1,316.30 euros on Lang & Schwarz at 08:13 CET on Monday, November 16, 0.93 percent above the Xetra close of Friday, November 13, at EUR 1,304.20.

Launch Execution Becomes The Next Test

Orforglipron, marketed as Foundayo in the United States, will compete in China with Lilly's weekly injectable obesity treatment and products from Novo Nordisk, Pfizer and local drugmakers. The GLP-1 class reduces appetite and helps regulate blood sugar.

The Chinese approval opens a pill-based route in a market where regulators had previously approved GLP-1 medicines for weight management only as injections. Lilly now faces the commercial tasks of pricing, supply and market access as competition builds.

Broader risk appetite can shape the setting for US equities, including the S&P 500.

More news and analyses on Eli Lilly stock.

Disclaimer...
en | US5324571083 | ELI LILLY AND CO. | boerse | 70519669 | bgmi